(Q37232214)

19 August 2017

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration (English)

1 reference

19 August 2017

11

Bryan P Schneider

1 reference

19 August 2017

8

Milan Radovich

1 reference

19 August 2017

John W Kitchens

1

1 reference

19 August 2017

Nawal Kassem

2

1 reference

19 August 2017

William Wood

3

1 reference

19 August 2017

Thomas W Stone

4

1 reference

19 August 2017

Rick Isernhagen

5

1 reference

19 August 2017

Edward Wood

6

1 reference

19 August 2017

Brad A Hancock

7

1 reference

19 August 2017

Josh Waymire

9

1 reference

19 August 2017

Lang Li

10

1 reference

19 August 2017

language of work or name

English

0 references

publication date

10 October 2013

1 reference

19 August 2017

Clinical Ophthalmology

1 reference

19 August 2017

7

1 reference

19 August 2017

1987-1993

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

19 August 2017

start time

1 October 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

The association of age-related maculopathy susceptibility 2 polymorphisms with phenotype in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Preferred therapies for neovascular age-related macular degeneration

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Ranibizumab for neovascular age-related macular degeneration

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Prevalence of age-related macular degeneration in the United States

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Association of LOC387715 A69S genotype with visual prognosis after photodynamic therapy for polypoidal choroidal vasculopathy

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3797648

Neovascular age-related macular degeneration and its association with LOC387715 and complement factor H polymorphism

3 September 2018

1 reference

12 December 2020

Role of Vascular Endothelial Growth Factor Polymorphisms in the Treatment Success in Patients with Wet Age-related Macular Degeneration

1 reference

12 December 2020

LOC387715/HTRA1 variants and the response to combined photodynamic therapy with intravitreal bevacizumab for polypoidal choroidal vasculopathy

1 reference

12 December 2020

Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration

1 reference

12 December 2020

Identifiers

DOI

10.2147/OPTH.S39635

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

24143065

1 reference